Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Therapy of GVHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. First allogeneic hematopoietic cell transplantation (second transplants are rare, typically performed for relapse of leukemia, in which case the likelihood of relapse is high, and there is the theoretical risk of increasing the likelihood further with ATG).~2. Conditioning including ATG 4.5 mg/kg (the predictive value of IL15 and IL2Ra levels was determined in patients whose conditioning included 4.5 mg/kg or ATG).~3. Age \>17 (the predictive value of IL15 and IL2Ra levels has not been studied in children).~Exclusion Criteria:~1. Nonmyeloablative conditioning (possible risk of ATG increasing relapse).~2. Active viral infection (risk of worsening of the viral infection with ATG).~3. Neutropenic fever with hypotension. In such case, the ATG can be given on day 9 (instead of day 8) if patient no longer has hypotension.~4. Hypoxemia. In such case, the ATG can be given on day 9 (instead of day 8) if patient no longer has hypoxemia.~5. History of anaphylactic reaction to Thymoglobulin or another rabbit blood protein.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention arm (Type: EXPERIMENTAL): Transplant recipients will have IL15 and IL2Ra measured on day 7. If at risk for significant GVHD, the patient will get rabbit antithymocyte globulin, 3 mg/kg on day 8.~Patients from this intervention/experimental arm will be compared to historical and concurrent controls (no ATG on day 8).

Based on this trial design, predict the completion outcome and termination type (if applicable).